Skip to main content
Equibles
CAI logo

CAI

Caris Life Sciences, Inc.
$16.99 -0.88 (-4.92%) At close · Jul 10
Market Cap
$4.80B
Shares
282,680,695

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.99 Open$17.95 Day$16.92–18.17 52W$14.43–42.50 Avg vol 30d2.7M Short int14.2M · 5.0% float · 4.3d Short vol48% Last earningsMay 7, 2026 DataJun 2025–Jul 2026 Filing10-Q · May 8
Up next
Next earnings call
Jul 31, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 8, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −25%
      below
      Price vs 50-day avg −1%
      below
      RSI (14) 45
      neutral
      MACD trend Negative
      52-week position 9%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −2%
      trailing
      6-month return −37%
      trailing
      YTD return −37%
      this year
      Relative strength −46%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $17 › 200d $23 — 200d above 50d
      Institutional flow Distributing
      7 of 202 funds reported for Jun 30 · net -302 sh shares · +1 new
      Insider flow Accumulating
      Net +$501.4K over 90 days · 0% sells
      Short interest Rising
      5.01% of float · ▲ +21.8% MoM · 4.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      202 holders — near 1-yr high, broad support
      Squeeze score 65
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +97%
      Y/Y
      EPS growth +70%
      Y/Y
      Free cash flow $66.9M
      Valuation P/E 48.5
      rich
      Balance sheet $417.8M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 63%
      annualized · 1-yr
      Max drawdown −63%
      past year
      ATR 6.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the 8-K filed May 7, 2026
      Total revenue · full year 2026 Initiated $1B – $1.02B
      prior FY $812.03M midpoint +24.4% Y/Y
      Clinical therapy selection volume growth · full year 2026 Initiated at least 20%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −25% Bearish
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      45 Neutral
      MACD trend
      Negative Bearish
      52-week position
      9% Bearish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $17 › 200d $23 — 200d above 50d
      Institutional flow Distributing
      7 of 202 funds reported for Jun 30 · net -302 sh shares · +1 new
      Insider flow Accumulating
      Net +$501.4K over 90 days · 0% sells
      Short interest Rising
      5.01% of float · ▲ +21.8% MoM · 4.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      202 holders — near 1-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $14 Now $17 · 9% 52-wk high $43
      vs 200-day avg -25% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      gross margin 65% Q1 2026 —
      quarterly run-rate completed cases (February and March) 56,000 Q1 2026 —
      ACHIEVE-1 high-risk cohort subjects 3,014 Q1 2026 call —
      activations growth (February and March) 20% Q1 2026 call —
      Caris Assure volume growth 58% Q1 2026 call —
      Caris Detect asymptomatic specificity 99.2% Q1 2026 call —
      Caris Detect benign tumor and high-risk patient specificity 96% Q1 2026 call —
      Caris Detect stage I and II sensitivity 60.3% Q1 2026 call —
      Caris Detect stage I sensitivity 56.8% Q1 2026 call —
      Caris Detect stage II sensitivity 67.7% Q1 2026 call —
      Caris Detect stage III sensitivity 79% Q1 2026 call —
      Caris Detect stage IV sensitivity 98.6% Q1 2026 call —
      cases completed 52,800 Q1 2026 call —
      clinical ASP increase 61% Q1 2026 call —
      full quarter activations growth 17% Q1 2026 call —
      matched profiles 790,000 Q1 2026 call —
      orders through EHR and portal channels 70% Q1 2026 call —
      physicians using EMR integrations 3,000 Q1 2026 call —
      Precision Oncology Alliance members 100 Q1 2026 call —
      sales territories 146 Q1 2026 call —
      therapy selection cases completed 52,800 Q1 2026 call —
      tissue cases 43,600 Q1 2026 call —
      volume growth 15% Q1 2026 call —
      whole transcriptomes 728,000 Q1 2026 call —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CAI
      Caris Life Sciences, Inc.
      this stock
      		$4.80B -37.0% — 48.5 5.0%
      ONC
      BeOne Medicines Ltd.
      		 $431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.19B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.67B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $54.85B +4.4% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      202
      % held
      54.3%
      Reported
      7 of 202
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      243
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      14.2M
      Days to cover
      4.3d
      Change
      +2.5M sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      22.2K
      Value
      $377.0K
      As of
      Jun 10, 2026
      View
      Off-Exchange
      Off-exchange %
      39.4%
      Week of
      Jun 15, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$501.4K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $812.0M
      Net income (FY)
      $-68.1M
      EPS diluted
      $-3.22
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $1.7M
      Shares
      62.3K
      Filed
      Dec 11, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 8, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CAI -7.2% -1.6% -37.4% -4.7% -37.0%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY -8.5% -5.7% -46.4% -5.8% -47.7%
      Key facts CIK 2019410 CUSIP 142152107 13F (30d) 6 filings 6 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)